Spritz RA. Recent progress in the genetics of generalized vitiligo[J]. J Genet Genomics, 2011, 38(7): 271⁃278. DOI: 10.1016/j.jgg.2011.05.005.
[2]
Lu T, Gao T, Wang A, et al. Vitiligo prevalence study in Shaanxi Province, China[J]. Int J Dermatol, 2007, 46(1): 47⁃51. DOI: 10.1111/j.1365⁃4632.2006.02848.x.
[3]
Jin Y, Birlea SA, Fain PR, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo[J]. N Engl J Med, 2010, 362(18): 1686⁃1697. DOI: 10.1056/NEJMoa0908547.
[4]
Tang XF, Zhang Z, Hu DY, et al. Association analyses identify three susceptibility Loci for vitiligo in the Chinese Han population[J]. J Invest Dermatol, 2013, 133(2): 403⁃410. DOI: 10.1038/jid.2012.320.
[5]
Thomas G, Sinville R, Sutton S, et al. Capillary and microelec⁃trophoretic separations of ligase detection reaction products produced from low⁃abundant point mutations in genomic DNA[J]. Electrophoresis, 2004, 25(10⁃11): 1668⁃1677. DOI: 10.1002/elps.200405886.
[6]
Yi P, Chen Z, Yu L, et al. Development of a PCR/LDR/capillary electrophoresis assay with potential for the detection of a beta⁃thalassemia fetal mutation in maternal plasma[J]. J Matern Fetal Neonatal Med, 2010, 23(8): 920⁃927. DOI: 10.3109/14767050903387060.
[7]
Purcell S, Neale B, Todd⁃Brown K, et al. PLINK: a tool set for whole⁃genome association and population⁃based linkage analyses[J]. Am J Hum Genet, 2007, 81(3): 559⁃575. DOI: 10.1086/519795.
[8]
Quan C, Ren YQ, Xiang LH, et al. Genome⁃wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC[J]. Nat Genet, 2010, 42(7): 614⁃618. DOI: 10.1038/ng.603.
[9]
Cho SB, Kim JH, Cho S, et al. Vitiligo in children and adolescents: association with thyroid dysfunction[J]. J Eur Acad Dermatol Venereol, 2011, 25(1): 64⁃67. DOI: 10.1111/j.1468⁃3083.2010.03694.x.
[10]
Bowcock AM, Fernandez⁃Vina M. Targeting skin: vitiligo and autoimmunity[J]. J Invest Dermatol, 2012, 132(1): 13⁃15. DOI: 10.1038/jid.2011.353.
[11]
Ruiz⁃Argüelles A, García⁃Carrasco M, Jimenez⁃Brito G, et al. Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study[J]. Clin Exp Immunol, 2013, 174(2): 229⁃236. DOI: 10.1111/cei.12168.